{
    "clinical_study": {
        "@rank": "109421", 
        "arm_group": [
            {
                "arm_group_label": "Phase I part", 
                "arm_group_type": "Experimental", 
                "description": "at least 21 patients with EGFR mutations"
            }, 
            {
                "arm_group_label": "Phase II part arm 1", 
                "arm_group_type": "Experimental", 
                "description": "20 patients must have advanced NSCLC with EGFR mutation (L858R or ex19del, not T790M)"
            }, 
            {
                "arm_group_label": "Phase II part arm 2", 
                "arm_group_type": "Experimental", 
                "description": "80 patients must have advanced NSCLC with an acquired T790M EGFR mutation"
            }, 
            {
                "arm_group_label": "Phase II part arm 3", 
                "arm_group_type": "Experimental", 
                "description": "80 patients must have advanced NSCLC with a \"de novo\" T790M EGFR mutation"
            }, 
            {
                "arm_group_label": "Phase II part arm 4", 
                "arm_group_type": "Experimental", 
                "description": "10 patients must have an advanced solid tumor harboring any EGFR mutation; and NOT be otherwise eligible for groups 1-3"
            }
        ], 
        "brief_summary": {
            "textblock": "To estimate the maximum tolerated dose (MTD) or recommended dose for expansion (RDE) of\n      EGF816 and to investigate the anti-tumor activity of EGF816"
        }, 
        "brief_title": "A Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid Malignancies", 
        "completion_date": {
            "#text": "September 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "NSCLC", 
        "condition_browse": {
            "mesh_term": "Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        - Written informed consent must be obtained prior to any screening procedures\n\n        Phase I part only:\n\n        - Patient must have an advanced solid tumor with any documented EGFR mutation.\n\n        Phase II part only:\n\n          -  Group 1: patients must have advanced NSCLC with EGFR mutation (L858R or ex19del, not\n             T790M)\n\n          -  Group 2: patients must have advanced NSCLC with an acquired T790M EGFR mutation\n\n          -  Group 3: patients must have advanced NSCLC with a \"de novo\" T790M EGFR mutation.\n\n          -  Group 4: patients must have an advanced solid tumor  harboring any EGFR mutation; and\n             NOT be otherwise eligible for groups 1-3\n\n          -  ECOG performance status \u2264 2\n\n          -  Presence of at least one measurable lesion according to RECIST v1.1\n\n        Exclusion Criteria:\n\n        Phase I part only:\n\n        - Patient have received more than 3 previousanti-neoplastic therapies in the advanced\n        setting\n\n        Phase II part only:\n\n          -  Group 1:More than total of 3 previous anti-neoplastic treatments in the advanced\n             setting\n\n          -  Group 2: More than total of 2 previous anti-neoplastic therapies in the advanced\n             setting\n\n          -  Group 3: More than total of 2 previous anti-neoplastic therapies in the advanced\n             setting\n\n          -  Group 4: More than total of 3 previous anti-neoplastic treatments in the advanced\n             setting.\n\n          -  Patients with brain metastases\n\n          -  Any medical condition that would, in the investigator's judgment, prevent the\n             patient's participation in the clinical study due to safety concerns or compliance\n             with clinical study procedures.\n\n          -  Patient have out of range laboratory values defined as\n\n               -  Bone marrow function\n\n               -  Absolute Neutrophil Count (ANC) <1.5 x 109/L\n\n               -  Hemoglobin (Hgb) <9 g/dL\n\n               -  Platelets <100 x 109/L\n\n               -  Hepatic and renal function\n\n               -  Total bilirubin >1.5 x upper limit of normal (ULN). For patients with Gilbert's\n                  syndrome total bilirubin >2.5 x upper limit of normal (ULN).\n\n               -  Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) >3 x ULN\n\n          -  Patients with tumor involvement of the liver must have AST and/or ALT >5 x ULN\n\n             \u2022 Serum creatinine >1.5 x ULN and/or measured creatinine clearance < 75% LLN\n\n          -  Patients receiving treatment with medications that are known to be 1) strong\n             inhibitors or inducers of CYP3A4/5; 2) CYP2D6 substrate with narrow therapeutic index"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "211", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 7, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02108964", 
            "org_study_id": "CEGF816X2101"
        }, 
        "intervention": {
            "arm_group_label": [
                "Phase I part", 
                "Phase II part arm 1", 
                "Phase II part arm 2", 
                "Phase II part arm 3", 
                "Phase II part arm 4"
            ], 
            "description": "EGF816 will be dosed once daily. On the first day of each cycle, patient will receive a prescription of adequate drug supply for self-administration at home. The investigator must emphasize compliance and will instruct the patient to take EGF816 exactly as prescribed.", 
            "intervention_name": "EGF816", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "NSCLC,", 
            "EGFRmut -TKI,", 
            "EGF816,", 
            "EGFRmut solid malignancies"
        ], 
        "lastchanged_date": "April 7, 2014", 
        "number_of_arms": "5", 
        "official_title": "A Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid Malignancies", 
        "overall_contact": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone": "+41613241111"
        }, 
        "overall_contact_backup": {
            "last_name": "Novartis Pharmaceuticals"
        }, 
        "overall_official": {
            "affiliation": "Novartis Pharmaceuticals", 
            "last_name": "Novartis Pharmaceuticals", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Canada: Health Canada"
            ]
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "September 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Maximum tolerated dose/Recommended dose for expansion (MTD)/RDE)", 
                "measure": "Phase I Part: Incidence of dose limiting toxicity (DLT)", 
                "safety_issue": "Yes", 
                "time_frame": "first 28 days of dosing"
            }, 
            {
                "description": "ORR (Overall respnse rate ). Overall respnse rate is the proportion of patients with a best overall response of complete response (CR) or partial respose (PR) according to RECIST 1.1 criteria", 
                "measure": "Phase II Part: Overall response rate (ORR)", 
                "safety_issue": "No", 
                "time_frame": "baseline, every 8 weeks until disease progression, consent withdraw or death up to 3 years"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02108964"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Best overall response (BOR). BOR is the best response recorded from the start of the treatment until disease progression/recurrence (taking as reference for PD the smallest measurements recorded since the treatment started).", 
                "measure": "Best overall response", 
                "safety_issue": "No", 
                "time_frame": "baseline, every 8 weeks until disease progression, consent withdraw or death  up to 3 years"
            }, 
            {
                "description": "Progression-free survival (PFS). PFS is the time from date of randomization/start of treatment to the date of event defined as the first documented progression or death due to any cause according to RECIST 1.1 criteria", 
                "measure": "Progression-free survival", 
                "safety_issue": "No", 
                "time_frame": "baseline, every 8 weeks until disease progression, consent withdraw or death  up to 3 years"
            }, 
            {
                "description": "Duration of response (DOR). For patients with a CR or PR (which may have to be confirmed the start date is the date of first documented response (CR or PR) and the end date and censoring is defined the same as that for time to progression.", 
                "measure": "Duration of response", 
                "safety_issue": "No", 
                "time_frame": "baseline, every 8 weeks until disease progression, consent withdraw or death  up to 3 years"
            }, 
            {
                "description": "To characterize EGF816 as a measure of safety", 
                "measure": "Frequency/severity of adverse events (AEs)", 
                "safety_issue": "Yes", 
                "time_frame": "continuously during study until 30 days after safety follow up"
            }, 
            {
                "description": "Plasma concentration vs. time profiles, plasma PK parameters", 
                "measure": "Pharmacokinetics properties of EGF816 and metabolite LMI258", 
                "safety_issue": "No", 
                "time_frame": "cycle 1 day 1,2,8, 15; cycle 2 day 1, 2; cycle 3 day 1; cycle 4 day 1"
            }, 
            {
                "description": "Pre- and post- treatment immunohistochemistry of EGFR pathway molecules", 
                "measure": "the tumor EGFR signaling inhibition by EGF816", 
                "safety_issue": "No", 
                "time_frame": "baseline and cycle 1 day 15"
            }, 
            {
                "description": "To characterize the EGF816 as a measure of tolerability.", 
                "measure": "Number of Dose interruptions and reductions", 
                "safety_issue": "Yes", 
                "time_frame": "continuously throughout the study until 30 days after safety follow up"
            }, 
            {
                "description": "To characterize EGF816 as a measure of safety", 
                "measure": "Frequency/severity of serious adverse events (SAEs)", 
                "safety_issue": "Yes", 
                "time_frame": "continuously during study until 30 days after safety follow up"
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}